News

Jul 3, 2017

Circadin® 2mg (prolonged-release melatonin) is now funded for insomnia in children and adolescents with Neurodevelopmental Disorders in New Zealand

Jun 25, 2017

Circadin® 2mg (prolonged-release melatonin) is now commercially available in Argentina

Mar 29, 2017

Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Spain (Read more)

Mar 13, 2017

Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Biocodex in France (Read more)

Dec 6, 2016

Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Kuhnil Pharmaceutical in South Korea (Read more)

Nov 16, 2016

Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Australia and New Zealand (Read more)

Nov 2, 2016

Neurim Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase III Trial of Paediatric Prolonged-Release Melatonin (“PedPRM”) for Sleep Disturbances in Children with Autism Spectrum Disorders (ASD) (Read more)

Oct 5, 2016

Circadin® 2mg (prolonged-release melatonin) is now commercially available in Honduras

Sep 28, 2016

Neurim Pharmaceuticals announces first patients’ enrollments in ReCOGNITION – phase II clinical trial of Piromelatine for mild Alzheimer’s disease (Read more)

Aug 2, 2016

Circadin® receives marketing authorization in Honduras

Jun 21, 2016

Circadin® is now reimbursed under a Temporary Recommendation for Use (RTU) in France for Children with Neurodevelopmental Disorders (Read more)

Mar 3, 2016

Circadin® 2mg (prolonged-release melatonin) is now commercially available in Peru

Mar 2, 2016

Circadin® 2mg (prolonged-release melatonin) is now commercially available in Argentina

Jan 11, 2016

Circadin® 2mg (prolonged-release melatonin) is now commercially available in South Africa

Oct 1, 2015

Circadin® 2mg (prolonged-release melatonin) is now commercially available in Colombia

Sep 18, 2015

Circadin® receives marketing authorization in Peru

Mar 2, 2015

Vigisom® 2mg (prolonged-release melatonin) is now commercially available in Chile

Sep 7, 2014

Circadin® receives marketing authorization in South Africa

Sep 1, 2014

Circadin® receives marketing authorization in South Korea

Aug 27, 2014

Neurim Pharmaceuticals initiates Phase III study of Paediatric Prolonged-Release Melatonin in children with Autistic Spectrum Disorders, suffering from sleep disturbances